期刊文献+

HPLC法测定阿伐那非中间体4-(3-氯-4-甲氧基苄胺基)-2-甲硫基-5-乙氧羰基嘧啶的有关物质 被引量:1

Determination of Related Substances in 4-(3-Chloro-4-methoxybenzylamino)-2-methylthio-5-ethoxycarbonyl pyrimidine as Intermediate of Avanafil by HPLC
下载PDF
导出
摘要 建立高效液相色谱法测定阿伐那非中间体4-(3-氯-4-甲氧基苄胺基)-2-甲硫基-5-乙氧羰基嘧啶(M-1)的有关物质。以C18为填充物的不锈钢柱及紫外检测器,在254 nm波长下,以0.02 mol/L磷酸二氢钾水溶液(用1 mol/L氢氧化钾溶液调节pH=5.5)-乙腈进行梯度洗脱,以主成分自身对照法计算。M-1与4个已知杂质均可达到基线分离,在各自浓度范围内线性关系良好,精密度试验的RSD均不大于2%,平均回收率99.16%~100.44%,RSD 0.69%~1.03%,检测限0.020~0.15μg/mL,定量限0.061~0.45μg/mL。该方法操作简便,准确度、专属性良好,可满足中间体M-1的质量控制要求。 To establish a HPLC method for the determination of related substances in 4-(3-chloro-4-methoxybenzylamino)-2-methylthio-5-ethoxycarbonyl pyrimidine(M-1)as an intermediate of Avanafil.The determination was performed on a C18 column and UV absorbance detector at a wavelength of 254 nm,0.02 mol/L potassium dihydrogen phosphate solution(pH was adjusted to 5.5 with 1 mol/L potassium hydroxide solution)and acetonitrile were used as the gradient elution reagents.The principal component self-control comparison method was used to calculate the content of the impurities.M-1 and four known impurities could achieve a baseline separation,and the linear relationship was good within their respective concentration ranges;RSD of precision test was no more than 2%,the average recovery rate was 99.16%~100.44%;and the RSD was 0.69%~1.03%;the limit of detection was 0.020~0.15μg/mL;the limit of quantification was 0.061~0.45μg/mL.This method was accurate,specific,simple and easy to operate,which was suitable for the quality control of the M-1.
作者 王帆 杨琪 李帅 郭新艳 孙清 WANG Fan;YANG Qi;LI Shuai;GUO Xin-yan;SUN Qing(Shandong Academy of Pharmaceutical Sciences,Key Laboratory for Biological Drug Research of Shandong Province,Jinan 250101,China)
出处 《精细化工中间体》 CAS 2022年第6期85-89,共5页 Fine Chemical Intermediates
基金 山东省重点研发计划(重大科技创新工程项目)(2021ZDSYS07)。
关键词 阿伐那非 中间体 有关物质 高效液相色谱法 Avanafil intermediates related substances HPLC
  • 相关文献

参考文献4

二级参考文献19

  • 1US FDA. FDA approves Stendra for erectile dysfunction[ EB/ OL ]. [ 2012 - 04 - 27 ]. http ://www. fda. gov/NewsEven- ts/Newsroom/PressAnnouneements/ucm302140, htm.
  • 2YAMADA K,MATSUKI K, OMORI K,et al. Aromatic ni- trogen-containing 6-membered cyclic compounds : US, 6797709 [ P ]. 2004 - 09 - 28.
  • 3LUE T F, GIULIANO F, MONTORSI F, et al. Summary of the recommendations on sexual dysfunctions in men [ J ]. J Sex Med,2004,1 (1) : 6 -23.
  • 4DEAN R C, LUE T F. Physiology of penile erection and pathophysiology of erectile dysfunction [ J ]. Urol Clin North Am,2005,32(4) : 379 -395.
  • 5Kedia GT,Uckert S,Assadi-Pour F,et al.Avanafil for the treatment of erectile dysfunction:initial data and clinical key properties[J] .Ther Adv Urol,2013,5(1):35-41.
  • 6Hellstrom WJ,Freier MT,Serefoglu EC,et al.A phase Ⅱ,single-blind,randomized,crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction[J] .BJU Int,2013,111(1):137-147.
  • 7Swearingen D,Nehra A,Morelos S,et al.Hemodynamic effect ofavanafil and glyceryl trinitrate coadministrastion[J] .Drugs Context,2013,26:212248.
  • 8ISmith WB,McCaslin IR,Gokce A,et al.PDE5 inhibitors:considerations for preference and long-term adherence[J] .Int J Clin Pract,2013,67(8):768-780.
  • 9Gur S,Kadowitz PJ,Gokce A,et al.Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension[J] .Curr Drug Metab.2013,14(2):265-269.
  • 10Goldstein I,McCullough AR,Jones LA,et al.A randomized,double-blind,placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction[J] .J Sex Med,2012,9(4):1122-1133.

共引文献9

同被引文献6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部